ChIP-on-chip analysis identifies IL-22 as direct target gene of ectopically expressed FOXP3 transcription factor in human T cells
- Andreas Jeron1, 2Email author,
- Wiebke Hansen3,
- Franziska Ewert2,
- Jan Buer3,
- Robert Geffers†4Email author and
- Dunja Bruder†1, 2
© Jeron et al.; licensee BioMed Central Ltd. 2012
Received: 26 April 2012
Accepted: 20 November 2012
Published: 17 December 2012
The transcription factor (TF) forkhead box P3 (FOXP3) is constitutively expressed at high levels in naturally occurring CD4+CD25+ regulatory T cells (nTregs). It is not only the most accepted marker for that cell population but is also considered lineage determinative. Chromatin immunoprecipitation (ChIP) of TFs in combination with genomic tiling microarray analysis (ChIP-on-chip) has been shown to be an appropriate tool for identifying FOXP3 transcription factor binding sites (TFBSs) on a genome-wide scale. In combination with microarray expression analysis, the ChIP-on-chip technique allows identification of direct FOXP3 target genes.
ChIP-on-chip analysis of the human FOXP3 expressed in resting and PMA/ionomycin–stimulated Jurkat T cells revealed several thousand putative FOXP3 binding sites and demonstrated the importance of intronic regions for FOXP3 binding. The analysis of expression data showed that the stimulation-dependent down-regulation of IL-22 was correlated with direct FOXP3 binding in the IL-22 promoter region. This association was confirmed by real-time PCR analysis of ChIP-DNA. The corresponding ChIP-region also contained a matching FOXP3 consensus sequence.
Knowledge of the general distribution patterns of FOXP3 TFBSs in the human genome under resting and activated conditions will contribute to a better understanding of this TF and its influence on direct target genes, as well as its importance for the phenotype and function of Tregs. Moreover, FOXP3-dependent repression of Th17-related IL-22 may be relevant to an understanding of the phenomenon of Treg/Th17 cell plasticity.
KeywordsFOXP3 ChIP-on-chip Jurkat T cells Transcription factor binding sites IL-22
To prevent inflammation-related collateral tissue damage and immune pathology caused by an excessive immune response to autoimmune-related self-antigens or pathogen-associated antigens, the immune system has developed a diverse spectrum of mechanisms allowing efficient regulation and suppression of innate and adaptive immune responses that maintain a homeostatic environment. One important cellular component mediating the control of immune responses is regulatory T cells (Tregs), which comprise various subpopulations. The so-called naturally occurring Treg cells (nTregs) have been described as being CD4+ T cells expressing high levels of the interleukin-2 receptor alpha-chain (known as CD25) and exhibiting immune-suppressive capability to self- and non-self-antigens . The nTregs develop in the thymus along with conventional T cells and are considered to be the primary component for the establishment and maintenance of peripheral immunological self-tolerance . Later it has been found that nTregs in mice can be identified by the expression of the transcription factor (TF) forkhead box P3 (Foxp3) .
Mutations in the human FOXP3 gene are linked to the Immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX), which is accompanied by a defect in the development of nTregs. This defect affects the peripheral tolerance and surveillance of auto-reactive T cells, thereby promoting systemic autoimmunity .
Interestingly, most mutations can be mapped to the forkhead-binding protein domain (FKH) , which mediates the general interaction of FOXP3 with genomic DNA  and with FOXP3 transcription factor binding sites (TFBSs) in particular. TFBSs can be defined by consensus sequences that have been determined for FOXP3 in several studies. De novo identification of human FOXP3 consensus sequences revealed the sequence 5′-GTAAACAA-3′. Furthermore, in vitro optimization studies demonstrated that the sequence 5′-GTAAACA-3′ is preferred for FOXP3 binding to DNA .
The human FOXP3 gene consists of 11 exons encoding for various splice variants. Besides the full-length 431 aa variant, three truncated transcript variants lacking exon 2 (FOXP3Δ2), exon 7 (FOXP3Δ7), or both (FOXP3Δ2,Δ7) have been described [9, 10]. However, the full-length and the Δ2 variant are the main isoforms and are equally expressed in resting human nTreg cells . Generally, all isoforms share the same protein domain entities: an N-terminal repressor domain, a C2H2 zinc-finger domain, a leucine zipper domain and a C-terminal FKH domain, which also contains a nuclear localization signal. Although all known FOXP3 isoforms share the FKH domain, it is important to note that FOXP3 can also act as a co-regulator independent of the FKH binding domain [11, 12].
Currently, the only contribution of FOXP3 to a full nTreg phenotype that can be defined either by gene expression patterns or on a functional level exhibiting the whole bandwidth of nTreg suppressive mechanisms is under constant controversial discussion, especially in the human system [13–15]. Nevertheless, because of their immune modulatory capability Tregs are considered key candidates for therapeutic interventions aimed at treating a broad variety of immunological diseases. If we are to better define the role of FOXP3 within nTregs, we must first gain knowledge about its condition-dependent global binding behavior, about its functional TFBSs throughout the genome, and about its competence in regulating the expression of adjacent genes.
Here we present the results of chromatin immunoprecipitation in combination with genomic tiling microarray (ChIP-on-chip) analysis of FOXP3Δ2, one of the main human FOXP3 isoforms, ectopically expressed in a Jurkat T-cell line under resting and mitogen-stimulated conditions. The main focus of the study was to investigate direct FOXP3/DNA interaction mediated by means of the FKH having direct impact on adjacent gene loci. The analyses revealed global distribution characteristics of human FOXP3 TFBSs and identified the cytokine IL-22 as a previously unknown direct transcriptional target of FOXP3 in activated T cells.
Ectopically expressed FOXP3 suppresses IL-2 production in human T cells
To study FOXP3 TFBSs by ChIP-on-chip analysis, we generated a human T-cell line stably expressing FOXP3Δ2. Jurkat T cells were retrovirally transfected with either a viral construct expressing FOXP3Δ2 and green fluorescent protein (GFP) as a reporter (hereafter termed J-FOXP3) or an empty viral construct expressing only GFP (hereafter termed J-GFP). Transfected GFPhigh T cells were sorted and subsequently expanded in vitro.
Mapping of genomic FOXP3 binding regions
It has been previously demonstrated that FOXP3 binding capability is sensitive to cellular Ca2+ influx and that it can be dramatically increased in T cells upon stimulation with PMA and ionomycin . Therefore, we analyzed FOXP3 TFBSs in both resting and PMA/ionomycin–activated J-FOXP3 T cells in two independent replicate experiments involving a FOXP3-specific ChIP procedure, as described in Materials and Methods.
Our experiments identified 3343 ChIP regions in resting J-FOXP3 T cells and 3632 ChIP regions in stimulated J-FOXP3 T cells. More than 50% of these ChIP regions were smaller than 125 bp; this size provided a sufficient mapping resolution for the ChIP regions (data not shown). The number of ChIP regions per chromosome in general was positively correlated with the overall size of the chromosome (Pearson correlation coefficient rresting = 0.91 with p = 7.07 × 10-10 and rstimulated = 0.96 with p = 2.12 × 10-13; data not shown). A table of the identified FOXP3 ChIP regions and a visualized genomic map can be found in Additional File 1.
FOXP3 preferentially binds in intronic regions located +1.6 kb from TSS
To analyze the positional distribution of FOXP3 TFBS in reference to the TSS in more detail, we annotated the identified ChIP regions with the Genomic Position Annotation Tool (GPAT) . GPAT was used in the promoter search mode, and annotation results were restricted to the tiling array’s promoter coverage range (-10 kb to +2.45 kb around the TSS). GPAT annotation resulted in 1998 annotated ChIP regions referencing 2011 gene entities in resting J-FOXP3 T cells and in 2127 ChIP regions referencing 2024 gene entities in stimulated J-FOXP3 T cells. The distances from all annotated ChIP regions to the closest TSS are presented in a histogram (Figure 3B). Interestingly, the positional distribution of ChIP regions downstream of TSS shows a marked peak at an average distance of about +1.6 kb from TSS. This main peak can be considered to result from FOXP3-bound intronic ChIP regions. However, the ChIP region distribution appears similar in both resting and stimulated conditions. A random compilation of ChIP regions matching the experimental region size and frequency distribution was further analyzed and underlined the meaning of the experiment-driven output of genomic positions for FOXP3 binding.
Pathway analysis of gene entities that were derived by GPAT annotation and that represented potential direct FOXP3 target genes was performed with GeneGO software (Thomson Reuters, New York, USA, see Additional File 2). Especially under resting conditions, the analysis identified significant (p < 0.05) enrichment of genes involved in pathways for co-stimulation of T cells, such as the CD28, CD40, ICOS, and CTLA-4 signalling pathways. Genes involved in pathways with general importance for T-cell activation, such as the NFAT, AKT, calcium and cAMP signaling pathways, were also overrepresented (p < 0.05). Of note, the IL-17 signalling pathway also appeared to be affected (p < 0.05) in the presence of FOXP3 protein.
FOXP3 binding to certain promoter regions is associated with transcriptional changes
IL-22 is a direct transcriptional target of human FOXP3 transcription factor activity
Interestingly, a reproducible FOXP3 binding site can be found in proximity (3646 bp) to the IL-22 TSS, a finding suggesting that this site is responsible for the observed stimulation-dependent repression of IL-22 expression in PMA/ionomycin treated J-FOXP3 T cells. A prerequisite for a direct FOXP3 target gene is the occurrence of at least one FOXP3 binding site in the gene’s promoter region. Hence, under this aspect we analyzed the corresponding IL-22 promoter ChIP region (region ID: chr12.119, see Additional File 1) with a length of 36 bp. Figure 6B shows the DNA sequence of the IL-22 ChIP region on chromosome 12 and the corresponding FOXP3 FKH consensus sequence . Strikingly, in the middle of the ChIP region there was a perfectly matching FOXP3 consensus site with the following genomic coordinates: chr12 66937190 – 66937197 (hg18 reference assembly). Genomic site-specific real-time PCR of this binding region confirmed about 5-fold ChIP enrichment (Figure 6C).
We chose to identify the functional genomic sites of direct DNA occupation by FOXP3Δ2 protein by using a combination of matching ChIP-on-chip and expression microarray data from human FOXP3-expressing Jurkat T cells under resting and stimulated conditions. Mitogenic stimulation with PMA and ionomycin ensures a strong simultaneous and swift T-cell activation circumventing the upstream T-cell receptor signaling, thereby allowing efficient triggering of its downstream signaling events, including activation of protein kinase C and triggering of Ca2+ influx, both of which are known to increase FOXP3 binding to genomic DNA [6, 19]. Thus, our dataset allows us to distinguish FOXP3 binding and reversal of binding under resting conditions from alterations in FOXP3 binding behavior under stimulated conditions and to determine the direct impact on transcriptional alterations under the very same circumstances. Since in previous human FOXP3 ChIP studies by Sadlon and colleagues  and Bierzele and colleagues  only ChIP DNA from stimulated cell material has been analyzed, our dataset provides deeper insights into condition-dependent FOXP3 interaction with genomic DNA.
The tiling microarray we used interrogates proximal promoter regions of genes (basically -7.5 kb to +2.45 kb around the TSS), thereby defining comparatively narrow genomic regions predominantly with potential competence for direct transcriptional regulation of adjacent gene loci. We identified 3343 ChIP hits with proximity to 2011 GPAT-annotated gene entities under resting conditions and 3632 ChIP hits with proximity to 2024 GPAT-annotated gene entities under stimulated conditions. Of 410 markedly FOXP3-dependent transcripts, as defined by the expression microarray analysis, 90 (22%) were associated with at least one ChIP hit within the promoter coverage range of the tiling microarray. The discrepancy between the much higher number of gene entities with nearby FOXP3 ChIP hits within their promoter regions as opposed to the number of transcripts that are in fact transcriptionally altered has been observed in previous murine and human FOXP3 ChIP-on-chip studies as well [7, 20–22]. This finding stresses the apparent presence of numerous silent or ineffective yet specific FOXP3 binding events in proximal promoters. However, about the biological meaning of such silent binding events can be speculated, but may for instance be explained in part by the interaction of FOXP3 with other transcription factors that may attenuate or block its functional influence on the transcription of an adjacent gene.
Both the FOXP3Δ2 isoform and the FOXP3Δ7 isoform can inhibit T-cell activation  and contribute to the phenotype of human nTregs [32, 33]. However, FOXP3 exon 2, which encodes for a portion of the FOXP3 repressor domain, has been specifically shown to be essential for interaction with and repression of retinoic acid–related orphan receptors α and γt (RORα, RORγt) [34, 35]. Both the RORα and the RORγt TFs are in turn essential for Th17 commitment of T cells [36–38]. Thus, FOXP3 expression is considered a key element preventing the establishment of a full Th17 phenotype in T cells .
However, in the context of T-cell plasticity some reports indicate that human RORγt+FOXP3+ Tregs exhibit the characteristics of both Tregs and Th17 cells. Consistently, it has been shown that isolated IL-17 producing FOXP3+ T cells that express RORγt share features of conventional RORγt+ Th17 cells. Interestingly, RORγt+FOXP3+ Tregs cannot sufficiently produce IL-22 after PMA/ionomycin stimulation . Because we found that the presence of FOXP3 (even if exon 2 is missing) is sufficient to suppress the expression of the Th17-related cytokines IL-26 and, especially, IL-22, it is reasonable to speculate that the identified FOXP3 TFBS in the IL-22 promoter explains the inability of RORγt+FOXP3+ T cells to produce IL-22 on the transcriptional level.
We successfully applied a combination of the state-of-the-art ChIP-on-chip analysis and expression microarray analysis to identify direct transcriptional targets of the human TF FOXP3Δ2 expressed in Jurkat T cells under resting and mitogen-stimulated conditions. Our results demonstrate that FOXP3 prefers intronic regions, independent of the cellular activation status. Notably, we found that genes important for the co-stimulation of T cells are transcriptional targets of FOXP3. In particular, we identified the Th17 lineage-related cytokine IL-22 as a previously unknown direct target gene of FOXP3. These results complete the picture of FOXP3 as a transcription factor and demonstrate its competence as a transcriptional regulator.
The FOXP3Δ2-expressing retrovirus (pRV-FOXP3Δ2-IRES-GFP) and the empty control virus (pRV-IRES-GFP) were generated as previously described [40, 41]. Briefly, the following primer pair was used to amplify the FOXP3Δ2 coding sequence from cDNA derived from human CD4+ T cells: 5′-cgggatccGGACAAGGACCCGATGCCCAACC-3′, 5′-CCCTGCCCCCACCACCTCTGC-3′. Retroviruses were transfected into PT67 packaging cell lines by calcium phosphate precipitation. Virus particles were produced by cultivating transfected PT67 cells for 24 h at 37°C in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 10% heat-inactivated fetal calf serum (FCS) and 100 U/ml penicillin/streptomycin. Remaining packaging cells were removed by filtering culture supernatants through a 0.2-μm syringe filter, after which 3 to 4 × 106 Jurkat T cells were resuspended in 2.5 ml of virus supernatant in a 6-well culture plate. Next, 2.5 μl polybrene (8 mg/ml Sigma-Aldrich, Steinheim, Germany) and 50 μl HEPES (Invitrogen, Darmstadt, Germany) were added per well. Cells were centrifuged at room temperature at 500 × g for 2 h and were further incubated for 24 h at 37°C. Transduction efficiency was checked by flow cytometry, and GFPhigh T cells were sorted with a BD FACSAria II cell sorter (Becton Dickinson [BD], Franklin Lakes, New Jersey, USA), followed by further cell expansion in IMDM.
Isolation of primary human T cells
CD4+CD25+FOXP3+ and naïve CD4+CD25+FOXP3- T cells were isolated from leukapheresis filters which were kindly provided by the Institute for Transfusion Medicine and Immune Hematology of the University Hospital Magdeburg. Cells were isolated using human CD4+CD25+ Regulatory T Cell Isolation Kit and AutoMACS device (both Miltenyi Biotec, Bergisch Gladbach, Germany) according to manufacturer’s instructions. Purity of isolated cells was checked by flow cytometry using CD3-FITC (clone OKT3, eBioscience, San Diego, CA, USA), CD4-PE-Cy7 (clone RPA-T4, eBioscience, San Diego, CA, USA) and CD25-PE (clone 4E3, Miltenyi Biotec, Bergisch Gladbach, Germany) antibody.
RNA was isolated by using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s recommendations. DNA was digested by using the RNase-Free DNase Set (Qiagen). RNA was eluted in 100 μl nuclease-free water and further concentrated by ethanol precipitation, beginning with the addition of 2 μl linear polyacrylamide (0.5 μg/μl,; Ambion, Darmstadt, Germany), 50 μl 7.5 M NH4OAc (Sigma-Aldrich), and 375 μl absolute ethanol, precooled to -20°C. RNA was precipitated for at least 2 h at -70°C and was then centrifuged at 14,000 × g at 4°C for 30 min in a table-top centrifuge. The RNA pellet was washed twice with 80% ethanol at -20°C, dried, and resuspended in nuclease-free water. RNA integrity was tested by using the Agilent 2100 Bioanalyzer (Agilent Technologies, Böblingen, Germany) with an Agilent RNA 6000 Nano/Pico Kit (Agilent Technologies).
Equal amounts of RNA were used for cDNA synthesis in a reverse transcription reaction using a mixture of 0.5 μl oligo-dT (0.5 μg/μl) and 0.5 μl random primers (3 μg/μl) and nuclease-free water (total volume, 12 μl). Samples were incubated for 10 min at 70°C and then put on ice for 10 min. Reverse transcription (RT) reaction mix was added, containing 4 μl 5x first-strand buffer (Invitrogen), 2 μl dithiothreitol (DTT; 0.1 M, Invitrogen), 1 μl dNTP Mix (10 mM, Invitrogen), and 1 μl SuperScript II Reverse Transcriptase (Invitrogen).
Samples were incubated for 60 min at 42°C in a thermocycler. Real-time PCR was performed in duplicate with LightCycler 480 SYBR Green I Master reaction mix (Roche, Mannheim, Germany) and a LightCycler 480 system (Roche). PCR reactions were performed with 1 μl cDNA, 5 μl primer mix (containing forward and reverse primer, 500 nmol/l each), 10 μl 2x concentrated LightCycler 480 SYBR Green I Master mix (Roche), and 4 μl nuclease-free water. Relative mRNA levels were determined by using standard curves for each gene, and quantitative normalization of gene expression was performed in relation to the expression of the housekeeping gene RPS9. As a template for the standard curves, a mixture of all samples in 4 serial dilutions was used, corresponding to 3, 1, 0.1, and 0.01 μl template amount. The following PCR temperature cycles were used (45 cycles were performed): Step 1: 95°C, 5 min; Step 2: 95°C, 10 sec; Step 3: 55-60°C (primer dependent), 10 sec; Step 4: 72°C, 10 sec; Step 5: 4°C, hold. Real-time PCR data were analyzed with LightCycler 480 software (Roche).
Confirmation of ChIP enrichment by site-specific genomic real-time PCR was performed by using amplified ChIP DNA from FOXP3-specific immunoprecipitation and from isotype control immunoprecipitation and in reference to an unrelated genomic region within the RPS9 gene. The following primers were used: RPS9 for: 5′-CGCAGGCGCAGACGGTGGAAGC-3′, RPS9 rev: 5′-CGAAGGGTCTCCGCGGGGTCACAT-3′, IL-2 for: 5′-GTCACAAACAGTGCACCTAC-3′, IL-2 rev: 5′-ATGGTTGCTGTCTCATCAGC-3′, FOXP3 for: 5′-GAACGCCATCCGCCACAACCTGA-3′, FOXP3 rev: 5′-CCCTGCCCCCACCACCTCTGC-3′, IL-22 for: 5′-CAACAGGCTAAGCACATGTCA-3′, IL-22 rev: 5′-ACTGTGTCCTTCAGCTTTTGC-3′, IL-26 for: 5′-AGCAACGATTCCAGAAGACC-3′, IL-26 rev: 5′-TGCAGTTGACCAAAAACGTC-3′, TGF-β2 for: 5′-CCAAAGGGTACAATGCCAAC-3′, TGF-β2 rev: 5′-CAGATGCTTCTGGATTTATGGTATT-3′, IL-22 chr12.119 for: 5′-AAGCCCACCTCCCAGGTCCC-3′, IL-22 chr12.119 rev: 5′-AGACAGCCAAAGCCTACTTCTGGT-3′
FOXP3 expression in transduced Jurkat T cells was detected by Western blot analysis. FOXP3 was detected by using monoclonal mouse anti-human FOXP3 antibody (clone 206D; Biolegend, San Diego, CA, USA; 1:1000 dilution in Tris buffered saline Tween 20 (TBS-T) buffer with 5% milk powder). For detection, a secondary polyclonal goat anti-mouse antibody conjugated to horseradish peroxidase (Dianova, Hamburg, Germany; 1:4000 in TBS-T buffer with 5% milk powder) was used.
Intracellular cytokine staining
For intracellular cytokine detection, cells were cultured in IMDM medium and re-stimulated with PMA (final concentration, 10 ng/ml) and ionomycin (final concentration, 1 μg/ml) for 4 h. For the final 2 h of incubation, brefeldin A (Sigma-Aldrich) was added to block the secretion of cytokines. Subsequently, cells were fixed with 1% (v/v) paraformaldehyde solution in phosphate-buffered saline (PBS). Cells were permeabilized with 0.1% IGEPAL (Sigma-Aldrich) in PBS for 5 min. IL-2 staining was performed for 30 min (mouse anti-human IL-2 APC, clone 5344.111; BD).
Jurkat T cells were cultivated in IMDM medium supplemented with 10% FCS (PAA Laboratories) and 100 U/ml penicillin/streptomycin. If stated, cells were stimulated with PMA (10 ng/ml, Sigma-Aldrich) and ionomycin (1 μg/ml, Sigma-Aldrich) for 4 h. Protein crosslinking was ensured by the addition of formaldehyde (1% v/v) and by incubation on a shaker for 10 min at room temperature. Formaldehyde was quenched for 5 min by the addition of glycine (125 mM final concentration). After centrifugation, the culture supernatant was removed, and cells were washed once with ice-cold PBS. Cells were lysed in IP cell-lysis Buffer (10 mM Tris HCL [pH 7.5], 10 mM NaCl, 3 mM MgCl2, 1 mM phenylmethanesulfonyl fluoride [PMSF] 0.5% v/v IGEPAL CA-630) and incubated on ice for 10 min. Lysed cells were centrifuged at 2500 rpm for 5 min at 4°C, and the supernatant was discarded. The chromatin material was obtained by lysing the cell nuclei with IP nuclei-lysis buffer (50 mM Tris HCL [pH 8.0], 10 mM EDTA, 1% [v/v] sodium dodecyl sulfate [SDS], complete protease inhibitors) and incubating them on ice for 10 min. Chromatin was diluted in IP dilution buffer (20 mM Tris HCl [pH 8], 2 mM EDTA, 1% v/v Triton X-100, 150 mM NaCl, 1 mM PMSF) and stored at -80°C.
ChIP chromatin corresponding to 5 × 107 cells was fragmented with a Branson Sonifier 250 (Branson Ultrasonics, Danbury, USA) equipped with a microtip. The following sonication conditions were applied: 60% duty cycle, maximum output power; 6 to 7 sonication cycles consisting of 30 sec on and 60 sec off. Average DNA fragment size was between 200 and 1000 bp. The IP process was performed essentially as described by the Affymetrix company: Protein G Sepharose 4B (Zymed, San Francisco, USA) and either 10 μg anti-human FOXP3 antibody (clone 206D, mouse IgG1,к; BioLegend) or 10 μg of isotype control antibody (clone MOPC-21, mouse IgG1,к; BioLegend) were used per IP, respectively.
After adapter ligation (adapter primer: 5′-GTTTCCCAGTCACGGTC(N)9-3′), ChIP DNA was amplified with a large-scale PCR reaction (amplification primer: 5′-GTTTCCCAGTCACGGTC-3′) involving Ampli Taq Gold DNA polymerase and partial incorporation of deoxyuridine triphosphate (dUTP). Amplified ChIP DNA was labelled and prepared for hybridization with the GeneChip WT Double-Stranded DNA Terminal Labeling Kit (Affymetrix) and was then analysed on a Human Promoter 1.0R tiling microarray (Affymetrix).
Tiling microarray data analysis
Basic tiling array data analysis was performed with TAS software (Version 1.1.02, Affymetrix). FOXP3-bound ChIP-enriched genomic regions were identified by comparing FOXP3 IP to a matched isotype control IP from the same cell material. Only continuous genomic regions exhibiting a p-value higher than the 95th percentile of all p-values were included in subsequent analyses. Both resting and PMA/ionomycin–stimulated conditions were analyzed in independent duplicate experiments. Each replicate experiment was analyzed separately. Calculated ChIP intervals were visualized with IGB software . The web-based Galaxy analysis tool  was used to compare repetitive ChIP-on-chip experiments. Positional intersecting ChIP regions between two replicate experiments were calculated; thus, these regions represented genomic regions that were identified in both ChIP-on-chip replicates. Moreover, the range of intersection was calculated, and only the corresponding genomic coordinates of intersecting areas were considered for further analysis. The tiling microarray data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus [44, 45] and are accessible through GEO Series accession number GSE37256 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE37256). Significance of the overlap between different lists of HGNC gene symbols was calculated using a hypergeometric test.
Expression microarray analysis
Equal amounts of RNA were amplified with a double linear amplification protocol, starting with the synthesis of double-stranded cDNA by using the T7dT23 primer (5′-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG(T)23-3′; Metabion, Planegg, Germany) and SuperScript II reverse transcriptase (Invitrogen, Karlsruhe, Germany). A second-strand cDNA synthesis was then performed with DNA polymerase I (Invitrogen) and E. coli DNA ligase (Invitrogen). After purification of double-stranded cDNA, the first amplification round was performed in an in vitro transcription reaction by using the Promega P1300 RiboMax Kit for T7 amplification (Promega, Mannheim, Germany); this procedure produced unlabeled cRNA. The amplified cRNA was subjected to a second amplification round, starting again with reverse transcription by using random hexamer primers (Pharmacia, Freiburg, Germany) for first-strand synthesis of cDNA, followed by cRNA degradation with RNase H treatment. T7dT23 primers were again used for the second-strand synthesis, as described above. In the second in vitro transcription, which used the GeneChip expression 3′-Amplification Reagent Kit for labeling (Affymetrix, San Francisco, CA, USA), biotinylated UTP was partially incorporated into the final cRNA. The quantity and quality of biotinylated cRNA were checked photometrically. Biotinylated cRNA was fragmented, hybridized to a Human Genome U133 Plus 2.0 Array (Affymetrix), washed, and stained as recommended by the manufacturer. Microarray data were analyzed with GeneSpring GX 10.0 software (Agilent Technologies) and the Robust Multi-array Analysis (RMA) normalization algorithm. Cluster analysis was performed with Genesis Software 1.7.3  by using a z-score transformation . A list of 410 FOXP3-dependent genes was compiled by combining two analysis strategies. First, J-FOXP3 cells were compared with J-GFP cells. Genes were considered to be influenced by the over-expressed FOXP3 protein only if their expression showed at least a two-fold change (up or down) under either stimulated or unstimulated conditions. In a second strategy, stimulated and resting J-FOXP3 and stimulated and resting J-GFP cells were compared by calculating the differences in gene expression. Only genes that showed at least a two-fold change in stimulation-dependent induction or repression were considered to be influenced by the over-expressed protein. Subsequently this list of stimulation-dependent transcripts was filtered for differences between FOXP3-expressing cells and GFP control cells. Only transcripts that exhibited at least a two-fold difference in stimulation dependency between J-FOXP3 and J-GFP cells were retained. Both analysis strategies resulted in a combined list of 410 FOXP3-dependent genes. The expression microarray data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus [44, 45] and are accessible through GEO Series accession number GSE37256 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE37256).
Forkhead box P3
Genomic Position Annotation Tool
Magnetic activated cell sorting
Phorbol 12-myristate 13-acetate
Transcription factor binding site
Regulatory T cell
Transcription start site.
This work was supported by the International Research Training group 1273 funded by the German Research Foundation (DFG). Dunja Bruder is supported by the President’s Initiative and Networking Fund of the Helmholtz Association of German Research Centers (HGF) under contract number W2/W3-029
- Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995, 155: 1151-1164.PubMed
- Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S: Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol. 1999, 162: 5317-5326.PubMed
- Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4 + CD25+ regulatory T cells. Nat Immunol. 2003, 4: 330-336.View ArticlePubMed
- Hannibal MC, Torgerson T, et al: IPEX Syndrome. Gene Reviews [Internet]. 1993, Seattle: University of Washington
- Ziegler SF: FOXP3: of mice and men. Annu Rev Immunol. 2006, 24: 209-226. 10.1146/annurev.immunol.24.021605.090547.View ArticlePubMed
- Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Stroud JC, Bates DL, Guo L, Han A, Ziegler SF, Mathis D, Benoist C, Chen L, Rao A: FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell. 2006, 126: 375-387. 10.1016/j.cell.2006.05.042.View ArticlePubMed
- Sadlon TJ, Wilkinson BG, Pederson S, Brown CY, Bresatz S, Gargett T, Melville EL, Peng K, D'Andrea RJ, Glonek GG, Goodall GJ, Zola H, Shannon MF, Barry SC: Genome-wide identification of human FOXP3 target genes in natural regulatory T cells. J Immunol. 2010, 185: 1071-1081. 10.4049/jimmunol.1000082.View ArticlePubMed
- Koh KP, Sundrud MS, Rao A: Domain requirements and sequence specificity of DNA binding for the forkhead transcription factor FOXP3. PLoS One. 2009, 4: e8109-10.1371/journal.pone.0008109.PubMed CentralView ArticlePubMed
- Kaur G, Goodall JC, Jarvis LB: Hill Gaston JS: Characterisation of Foxp3 splice variants in human CD4+ and CD8+ T cells–identification of Foxp3Delta7 in human regulatory T cells. Mol Immunol. 2010, 48: 321-332. 10.1016/j.molimm.2010.07.008.View ArticlePubMed
- Mailer RKW, Falk K, Rötzschke O: Absence of leucine zipper in the natural FOXP3Delta2Delta7 isoform does not affect dimerization but abrogates suppressive capacity. PLoS One. 2009, 4: e6104-10.1371/journal.pone.0006104.PubMed CentralView ArticlePubMed
- Lee S, Gao B, Fang D: FoxP3 maintains Treg unresponsiveness by selectively inhibiting the promoter DNA-binding activity of AP-1. Blood. 2008, 111: 3599-3606. 10.1182/blood-2007-09-115014.View ArticlePubMed
- Li B, Greene MI: FOXP3 actively represses transcription by recruiting the HAT/HDAC complex. Cell Cycle . 2007, 6: 1432-1436. (Georgetown, Tex.)PubMed
- Hori S: Rethinking the molecular definition of regulatory T cells. Eur J Immunol. 2008, 38: 928-930. 10.1002/eji.200838147.View ArticlePubMed
- Roncarolo M, Gregori S: Is FOXP3 a bona fide marker for human regulatory T cells?. Eur J Immunol. 2008, 38: 925-927. 10.1002/eji.200838168.View ArticlePubMed
- Zheng Y, Rudensky AY: Foxp3 in control of the regulatory T cell lineage. Nat Immunol. 2007, 8: 457-462. 10.1038/ni1455.View ArticlePubMed
- Chen C, Rowell EA, Thomas RM, Hancock WW, Wells AD: Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation. J Biol Chem. 2006, 281: 36828-36834. 10.1074/jbc.M608848200.View ArticlePubMed
- Ji H, Vokes SA, Wong WH: A comparative analysis of genome-wide chromatin immunoprecipitation data for mammalian transcription factors. Nucleic Acids Res. 2006, 34: e146-10.1093/nar/gkl803.PubMed CentralView ArticlePubMed
- Krebs A, Frontini M, Tora L: GPAT: retrieval of genomic annotation from large genomic position datasets. BMC Bioinforma. 2008, 9: 533-10.1186/1471-2105-9-533.View Article
- Samanta A, Li B, Song X, Bembas K, Zhang G, Katsumata M, Saouaf SJ, Wang Q, Hancock WW, Shen Y, Greene MI: TGF-beta and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc Natl Acad Sci USA. 2008, 105: 14023-14027. 10.1073/pnas.0806726105.PubMed CentralView ArticlePubMed
- Birzele F, Fauti T, Stahl H, Lenter MC, Simon E, Knebel D, Weith A, Hildebrandt T, Mennerich D: Next-generation insights into regulatory T cells: expression profiling and FoxP3 occupancy in Human. Nucleic Acids Res. 2011, 39: 7946-7960. 10.1093/nar/gkr444.PubMed CentralView ArticlePubMed
- Marson A, Kretschmer K, Frampton GM, Jacobsen ES, Polansky JK, MacIsaac KD, Levine SS, Fraenkel E, von Boehmer H, Young RA: Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature. 2007, 445: 931-935. 10.1038/nature05478.PubMed CentralView ArticlePubMed
- Zheng Y, Josefowicz SZ, Kas A, Chu T, Gavin MA, Rudensky AY: Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature. 2007, 445: 936-940. 10.1038/nature05563.View ArticlePubMed
- Seal RL, Gordon SM, Lush MJ, Wright MW, Bruford EA: Genenames.org: the HGNC resources in 2011. Nucleic Acids Res. 2011, 39: D514-D519. 10.1093/nar/gkq892.PubMed CentralView ArticlePubMed
- Karman J, Jiang J, Gumlaw N, Zhao H, Campos-Rivera J, Sancho J, Zhang J, Jiang C, Cheng S, Zhu Y: Ligation of cytotoxic T lymphocyte antigen-4 to the TCR inhibits T cell activation and directs differentiation into FOXP3+ regulatory T cells. J Biol Chem. 2012, 287 (47): 11098-11107.PubMed CentralView ArticlePubMed
- Ikeda T, Hirata S, Fukushima S, Matsunaga Y, Ito T, Uchino M, Nishimura Y, Senju S: Dual effects of TRAIL in suppression of autoimmunity: the inhibition of Th1 cells and the promotion of regulatory T cells. J Immunol. 2010, 185: 5259-5267. 10.4049/jimmunol.0902797.View ArticlePubMed
- Hermann-Kleiter N, Baier G: NFAT pulls the strings during CD4+ T helper cell effector functions. Blood. 2010, 115: 2989-2997. 10.1182/blood-2009-10-233585.View ArticlePubMed
- Grant C, Oh U, Fugo K, Takenouchi N, Griffith C, Yao K, Newhook TE, Ratner L, Jacobson S: Foxp3 represses retroviral transcription by targeting both NF-kappaB and CREB pathways. PLoS Pathog. 2006, 2: e33-10.1371/journal.ppat.0020033.PubMed CentralView ArticlePubMed
- Bettelli E, Dastrange M, Oukka M: Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci USA. 2005, 102: 5138-5143. 10.1073/pnas.0501675102.PubMed CentralView ArticlePubMed
- Ren X, Ye F, Jiang Z, Chu Y, Xiong S, Wang Y: Involvement of cellular death in TRAIL/DR5-dependent suppression induced by CD4(+)CD25(+) regulatory T cells. Cell Death Differ. 2007, 14: 2076-2084. 10.1038/sj.cdd.4402220.View ArticlePubMed
- Kitoh A, Ono M, Naoe Y, Ohkura N, Yamaguchi T, Yaguchi H, Kitabayashi I, Tsukada T, Nomura T, Miyachi Y, Taniuchi I, Sakaguchi S: Indispensable role of the Runx1-Cbfbeta transcription complex for in vivo-suppressive function of FoxP3+ regulatory T cells. Immunity. 2009, 31: 609-620. 10.1016/j.immuni.2009.09.003.View ArticlePubMed
- Smith EL, Finney HM, Nesbitt AM, Ramsdell F, Robinson MK: Splice variants of human FOXP3 are functional inhibitors of human CD4+ T-cell activation. Immunology. 2006, 119: 203-211. 10.1111/j.1365-2567.2006.02425.x.PubMed CentralView ArticlePubMed
- Aarts-Riemens T, Emmelot ME, Verdonck LF, Mutis T: Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(-) cells. Eur J Immunol. 2008, 38: 1381-1390. 10.1002/eji.200737590.View ArticlePubMed
- Allan SE, Passerini L, Bacchetta R, Crellin N, Dai M, Orban PC, Ziegler SF, Roncarolo MG, Levings MK: The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J Clin Invest. 2005, 115: 3276-3284. 10.1172/JCI24685.PubMed CentralView ArticlePubMed
- Du J, Huang C, Zhou B, Ziegler SF: Isoform-specific inhibition of ROR alpha-mediated transcriptional activation by human FOXP3. J Immunol. 2008, 180: 4785-4792.View ArticlePubMed
- Ichiyama K, Yoshida H, Wakabayashi Y, Chinen T, Saeki K, Nakaya M, Takaesu G, Hori S, Yoshimura A, Kobayashi T: Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J Biol Chem. 2008, 283: 17003-17008. 10.1074/jbc.M801286200.View ArticlePubMed
- Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, Ma L, Shah B, Panopoulos AD, Schluns KS, Watowich SS, Tian Q, Jetten AM, Dong C: T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity. 2008, 28: 29-39. 10.1016/j.immuni.2007.11.016.PubMed CentralView ArticlePubMed
- Zhang F, Meng G, Strober W: Interactions among the transcription factors Runx1, RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat Immunol. 2008, 9: 1297-1306. 10.1038/ni.1663.View ArticlePubMed
- Zhou L, Littman DR: Transcriptional regulatory networks in Th17 cell differentiation. Curr Opin Immunol. 2009, 21: 146-152. 10.1016/j.coi.2009.03.001.PubMed CentralView ArticlePubMed
- Ayyoub M, Deknuydt F, Raimbaud I, Dousset C, Leveque L, Bioley G, Valmori D: Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. Proc Natl Acad Sci USA. 2009, 106: 8635-8640. 10.1073/pnas.0900621106.PubMed CentralView ArticlePubMed
- Hansen W, Westendorf AM, Toepfer T, Mauel S, Geffers R, Gruber AD, Buer J: Inflammation in vivo is modulated by GPR83 isoform-4 but not GPR83 isoform-1 expression in regulatory T cells. Genes Immun. 2010, 11: 357-361. 10.1038/gene.2010.5.View ArticlePubMed
- Reinwald S, Wiethe C, Westendorf AM, Breloer M, Probst-Kepper M, Fleischer B, Steinkasserer A, Buer J, Hansen W: CD83 expression in CD4+ T cells modulates inflammation and autoimmunity. J Immunol. 2008, 180: 5890-5897.View ArticlePubMed
- Nicol JW, Helt GA, Blanchard SGJ, Raja A, Loraine AE: The Integrated Genome Browser: free software for distribution and exploration of genome-scale datasets. Bioinformatics. 2009, 25: 2730-2731. 10.1093/bioinformatics/btp472. (Oxford, England)PubMed CentralView ArticlePubMed
- Blankenberg D, Von Kuster G, Coraor N, Ananda G, Lazarus R, Mangan M, Nekrutenko A, Taylor J: Galaxy: a web-based genome analysis tool for experimentalists. Curr Protoc Mol Biol. 2010, 19 (10): 1-21. Chapter 19:Unit
- Edgar R, Domrachev M, Lash AE: Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002, 30: 207-210. 10.1093/nar/30.1.207.PubMed CentralView ArticlePubMed
- Barrett T, Troup DB, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Muertter RN, Holko M, Ayanbule O, Yefanov A, Soboleva A: NCBI GEO: archive for functional genomics data sets–10 years on. Nucleic Acids Res. 2011, 39: D1005-10. 10.1093/nar/gkq1184.PubMed CentralView ArticlePubMed
- Sturn A, Quackenbush J, Trajanoski Z: Genesis: cluster analysis of microarray data. Bioinformatics. 2002, 18: 207-208. 10.1093/bioinformatics/18.1.207. Oxford, EnglandView ArticlePubMed
- Cheadle C, Vawter MP, Freed WJ, Becker KG: Analysis of microarray data using Z score transformation. J Mol Diagn: JMD. 2003, 5: 73-81. 10.1016/S1525-1578(10)60455-2.PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.